The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
biotech startup archon biosciences aims to revolutionize antibody drug design
Archon Biosciences, a biotech startup co-founded by Nobel Prize winner David Baker, focuses on computational protein design to enhance biologic drugs through innovative "antibody cages." Launched with $20 million in seed funding, the company aims to improve antibody properties while minimizing changes to their structure. With plans for clinical trials and a financial runway into 2026, Archon is poised to make significant advancements in drug development.
nobel prize awarded for protein design and drug developments advance
David Baker, Demis Hassabis, and John Jumper have won the Nobel Prize in Chemistry for their groundbreaking work in computational protein design and structure prediction, significantly advancing drug design capabilities. Alnylam Pharmaceuticals seeks FDA approval for vutrisiran to treat a severe form of transthyretin amyloidosis, while Johnson & Johnson halts a bladder cancer trial for TAR-200. AstraZeneca invests in a preclinical cholesterol-lowering drug, and Astellas acquires rights to an experimental gene therapy for frontotemporal dementia.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.